Insights on Embolic Protection, Repositioning, and Stroke: A Subanalysis of the RESPOND Study

Table 1

Baseline characteristics in the RESPOND patient population, according to cerebral embolic protection use and valve repositioning.

Baseline characteristic	Embolic protection use			Valve repositioning
	No CEP	CEP	value	No REPOS.	REPOS.	value
	N = 904	N = 92		N = 683	N = 313
Age (years)	80.9 ± 6.5	80.0 ± 6.4	0.24	80.9 ± 6.3	80.5 ± 7.0	0.39
Gender (female)	49.9%	59.8%	0.07	52.0%	48.2%	0.27
BMI (kg/m^2)	27.3 ± 5.6	27.1 ± 5.0	0.84	27.4 ± 5.7	26.9 ± 5.1	0.22
STS score (%)	6.0 ± 7.0	5.8 ± 5.8	0.89	5.6 ± 6.0	6.8 ± 8.6	0.02
EuroSCORE 2011 (%)	8.1 ± 8.4	7.1 ± 8.2	0.28	8.0 ± 8.2	8.0 ± 8.8	0.98
Diabetes, medically treated	22.3%	23.1%	0.87	22.7%	21.7%	0.73
History of hyperlipidemia	54.4%	57.8%	0.54	54.5%	55.2%	0.82
History of hypertension	78.4%	86.8%	0.06	79.5%	78.5%	0.72
Porcelain aorta	3.9%	8.7%	0.05	4.4%	4.2%	0.86
Aortic valve calcification, severe (site-reported)	3.2.%	50.0%	<0.001	32.7%	36.4%	0.24
Hostile chest	0.8%	3.3%	0.06	0.9%	1.3%	0.52
History of cerebrovascular accident	9.2%	12.0%	0.39	8.5%	11.5%	0.13
History of coronary artery disease	55.9%	57.6%	0.76	56.7%	54.8%	0.58
History of congestive heart failure	35.5%	59.8%	<0.001	36.3%	40.8%	0.17
History of atrial fibrillation	34.5%	27.8%	0.20	34.5%	32.6%	0.55
Prior MI	14.8%	26.1%	<0.01	15.3%	17.2%	0.46
Prior PCI	29.5%	33.0%	0.49	29.6%	30.3%	0.81
Prior CABG	11.7%	18.5%	0.06	11.1%	15.0%	0.08
Prior pacemaker	13.7%	8.7%	0.18	13.3%	13.1%	0.92